论文部分内容阅读
近有报道,肿瘤相关胰蛋白酶抑制剂(TATI)是粘液性卵巢癌的一个潜在的肿瘤标记。已发现60%粘液性卵巢癌病人血清TATI值增高。测定卵巢恶性、交界性及良性粘液性肿瘤病人初次手术前TATI,同时与癌抗原标记125(CA125)的结果相比较,可估价TATI单独测定及与CA125联合测定的价值。根据WHO的病理组织学诊断标准,对30例卵巢粘液性肿瘤病人(恶性10例、交界性2例、良性18例)在术前及术中测定TATI及CA125。TATI通过放免法测定大于21μg/L及CA125通过放免及酶免法测定大于35U/ml定为不正常,两种CA125测定结果之间呈线性相关。
It has been recently reported that tumor associated trypsin inhibitor (TATI) is a potential tumor marker for mucinous ovarian cancer. It has been found in 60% of patients with mucinous ovarian cancer serum TATI value increased. To determine the presence of TATI in patients with ovarian malignant, borderline and benign mucinous neoplasms prior to initial surgery, and to assess the value of TATI alone or in combination with CA125 in comparison with the results of the cancer antigen marker 125 (CA125). According to WHO diagnostic criteria of histopathology, TATI and CA125 were measured preoperatively and intraoperatively in 30 patients with ovarian mucinous neoplasm (malignant 10, borderline 2, benign 18). TATI by radioimmunoassay greater than 21μg / L and CA125 by radioimmunoassay and determination of greater than 35U / ml was not normal, the results of two CA125 was linearly correlated.